Drug Type Antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism CD73 inhibitors(5-nucleotidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | China | 30 Jan 2022 |